IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE

Translated title of the contribution: Oral high dose of medroxyprogesterone acetate (MPA) in the treatment of advanced breast and endometrial carcinoma

M. R. Bernardo-Strada, E. Imparato, G. Aspesi, L. Pavesi, G. Robustelli Della Cuna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The results of a pilot study on the use of oral medroxyprogesterone acetate (Provera-Upjohn) at a high dose in a series of 50 consecutive women with advanced breast (30 cases) and endometrial carcinoma (20 cases) are reported. Patients with progressive disease, not liable to further conventional treatments, received MPA (500 mg/day orally) for 90 days. The evaluation of results has shown only partial responses: in 9/30 (30%) of women with disseminated breast carcinoma (median duration of response 10 months, median survival 15 months), and in 6/30 (30%) of patients with advanced endometrial carcinoma (median duration of response 15 months, median survival not reached at 28 months of follow-up). Even if with a lower response rate, as compared to the results obtained with parenteral formulation, the oral MPA maintains its therapeutic effectivenes in these hormone dependent tumors: easy to handle during long term treatment, oral MPA could be a useful alternative also for maintenance therapy.

Original languageItalian
Pages (from-to)3241-3246
Number of pages6
JournalMinerva Medica
Volume71
Issue number44
Publication statusPublished - 1980

Fingerprint

Medroxyprogesterone Acetate
Endometrial Neoplasms
Breast Neoplasms
Therapeutics
Survival
Breast
Hormones
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bernardo-Strada, M. R., Imparato, E., Aspesi, G., Pavesi, L., & Robustelli Della Cuna, G. (1980). IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE. Minerva Medica, 71(44), 3241-3246.

IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE. / Bernardo-Strada, M. R.; Imparato, E.; Aspesi, G.; Pavesi, L.; Robustelli Della Cuna, G.

In: Minerva Medica, Vol. 71, No. 44, 1980, p. 3241-3246.

Research output: Contribution to journalArticle

Bernardo-Strada, MR, Imparato, E, Aspesi, G, Pavesi, L & Robustelli Della Cuna, G 1980, 'IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE', Minerva Medica, vol. 71, no. 44, pp. 3241-3246.
Bernardo-Strada MR, Imparato E, Aspesi G, Pavesi L, Robustelli Della Cuna G. IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE. Minerva Medica. 1980;71(44):3241-3246.
Bernardo-Strada, M. R. ; Imparato, E. ; Aspesi, G. ; Pavesi, L. ; Robustelli Della Cuna, G. / IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE. In: Minerva Medica. 1980 ; Vol. 71, No. 44. pp. 3241-3246.
@article{279ece99a6804b3da99908b22d846311,
title = "IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE",
abstract = "The results of a pilot study on the use of oral medroxyprogesterone acetate (Provera-Upjohn) at a high dose in a series of 50 consecutive women with advanced breast (30 cases) and endometrial carcinoma (20 cases) are reported. Patients with progressive disease, not liable to further conventional treatments, received MPA (500 mg/day orally) for 90 days. The evaluation of results has shown only partial responses: in 9/30 (30{\%}) of women with disseminated breast carcinoma (median duration of response 10 months, median survival 15 months), and in 6/30 (30{\%}) of patients with advanced endometrial carcinoma (median duration of response 15 months, median survival not reached at 28 months of follow-up). Even if with a lower response rate, as compared to the results obtained with parenteral formulation, the oral MPA maintains its therapeutic effectivenes in these hormone dependent tumors: easy to handle during long term treatment, oral MPA could be a useful alternative also for maintenance therapy.",
author = "Bernardo-Strada, {M. R.} and E. Imparato and G. Aspesi and L. Pavesi and {Robustelli Della Cuna}, G.",
year = "1980",
language = "Italian",
volume = "71",
pages = "3241--3246",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "44",

}

TY - JOUR

T1 - IL MEDROSSIPROGESTERONE ACETATO (MPA) AD ALTA DOSE PER VIA ORALE NEL TRATTAMENTO DELLE FASI AVANZATE DEL CANCRO MAMMARIO ED ENDOMETRIALE

AU - Bernardo-Strada, M. R.

AU - Imparato, E.

AU - Aspesi, G.

AU - Pavesi, L.

AU - Robustelli Della Cuna, G.

PY - 1980

Y1 - 1980

N2 - The results of a pilot study on the use of oral medroxyprogesterone acetate (Provera-Upjohn) at a high dose in a series of 50 consecutive women with advanced breast (30 cases) and endometrial carcinoma (20 cases) are reported. Patients with progressive disease, not liable to further conventional treatments, received MPA (500 mg/day orally) for 90 days. The evaluation of results has shown only partial responses: in 9/30 (30%) of women with disseminated breast carcinoma (median duration of response 10 months, median survival 15 months), and in 6/30 (30%) of patients with advanced endometrial carcinoma (median duration of response 15 months, median survival not reached at 28 months of follow-up). Even if with a lower response rate, as compared to the results obtained with parenteral formulation, the oral MPA maintains its therapeutic effectivenes in these hormone dependent tumors: easy to handle during long term treatment, oral MPA could be a useful alternative also for maintenance therapy.

AB - The results of a pilot study on the use of oral medroxyprogesterone acetate (Provera-Upjohn) at a high dose in a series of 50 consecutive women with advanced breast (30 cases) and endometrial carcinoma (20 cases) are reported. Patients with progressive disease, not liable to further conventional treatments, received MPA (500 mg/day orally) for 90 days. The evaluation of results has shown only partial responses: in 9/30 (30%) of women with disseminated breast carcinoma (median duration of response 10 months, median survival 15 months), and in 6/30 (30%) of patients with advanced endometrial carcinoma (median duration of response 15 months, median survival not reached at 28 months of follow-up). Even if with a lower response rate, as compared to the results obtained with parenteral formulation, the oral MPA maintains its therapeutic effectivenes in these hormone dependent tumors: easy to handle during long term treatment, oral MPA could be a useful alternative also for maintenance therapy.

UR - http://www.scopus.com/inward/record.url?scp=0019194649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019194649&partnerID=8YFLogxK

M3 - Articolo

C2 - 7454090

AN - SCOPUS:0019194649

VL - 71

SP - 3241

EP - 3246

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 44

ER -